The coagulopathy of cancer

Current Opinion in Hematology

Volumn 21, Issue 5, 2014, Pages 423-429

  Falanga, Anna ^a   Russo, Laura ^a   Milesi, Viola ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

cancer; hemorrhage; hypercoagulable state; thromboprophylaxis; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIVITAMIN K; APIXABAN; BIOLOGICAL MARKER; D DIMER; DABIGATRAN; FIBRINOLYTIC AGENT; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; RIVAROXABAN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; LONG TERM CARE; METASTASIS; MULTIPLE MYELOMA; NEOPLASM; ONCOGENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; TUMOR CELL; TUMOR MICROENVIRONMENT; VENOUS THROMBOEMBOLISM; BLOOD COAGULATION DISORDERS; COMPLICATION;

BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84906086005     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000072     Document Type: Article

References (50)

1. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012; 32:115-125
2. Magnus N, Meehan B, Garnier D, Rak J. Oncogenes and the coagulation system - forces that modulate dormant and aggressive states in cancer. Thromb Res 2014; 133:S1-S9
3. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-Associated venous thrombosis. Blood 2013; 122:1712-1723
4. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56-70
5. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:2189-2204
6. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119:648-655
7. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-Analysis. PLoS Med 2012; 9:e1001275
8. Sanon S, Lenihan DJ, Mouhayar E. Peripheral arterial ischemic events in cancer patients. Vasc Med 2011; 16:119-130
9. Di Nisio M, Ferrante N, Feragalli B, et al. Arterial thrombosis inambulatory cancer patients treated with chemotherapy. Thromb Res 2011; 127:382-383
10. Kansu E. Thrombosis in stem cell transplantation. Hematology 2012; 17 (Suppl 1):S159-S162
11. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011; 17:5858-5866
12. Connolly GC, Menapace L, Safadjou S, et al. Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer 2013; 14:713-718
13. Van Es N, Bleker SM, Di Nisio M. Cancer-Associated unsuspected pulmonary embolism. Thromb Res 2014; 133:S172-S178
14. Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res 2012; 129 (Suppl 1):S66-S68
15. Breccia M, Coco FL. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res 2014; 133:S112-S116
16. Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37:1004-1009
17. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111-121
18. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res 2013; 131 (Suppl 1):S59-S62
19. Khorana AA, McCrae KR. Risk stratification strategies for cancer-Associated thrombosis: An update. Thromb Res 2014; 133:S35-S38
20. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: Biological and clinical aspects. J Thromb Haemost 2013; 11:223-233
21. Nadir Y, Brenner B. Heparanase multiple effects in cancer. Thromb Res 2014; 133:S90-S94
22. Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res 2012; 129 (Suppl 1):S132-S136
23. Stegner D, Dutting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res 2014; 133:S149-S157
24. Demers M, Wagner DD. Neutrophil extracellular traps: A new link to cancerassociated thrombosis and potential implications for tumor progression. Oncoimmunology 2013; 2:e22946
25. Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A 2014; 111:3544-3549
26. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122:2011-2018
27. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703-2708
28. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 θ 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124-4129
29. Zwicker JI, Liebman HA, Bauer KA, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: A randomized-controlled phase II trial (the Microtec study). Br J Haematol 2013; 160:530-537
30. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29:2099-2103
31. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-Associated thrombosis. Blood 2008; 111:4902-4907
32. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 2011; 29:3466-3473
33. Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: The 'SENDO experience'. Ann Oncol 2012; 23:1416-1421
34. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score. Intern Emerg Med 2012; 7:291-292
35. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomideand lenalidomide-Associated thrombosis in myeloma. Leukemia 2008; 22:414-423
36. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-Associated venous thromboembolism. Circulation 2012; 126:448-454
37. Den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-Associated thrombosis. J Thromb Haemost 2013; 11:998-1000
38. Di Castelnuovo A, De Curtis A, Costanzo S, et al. Association of D-dimer levels with all-cause mortality in a healthy adult population: Findings from the MOLI-SANI study. Haematologica 2013; 98:1476-1480
39. Amirkhosravi A, Bigsby G, Desai H, et al. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses. Blood Coagul Fibrinolysis 2013; 24:510-517
40. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebocontrolled, double-blind study. Lancet Oncol 2009; 10:943-949
41. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48:1283-1292
42. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366:601-609
43. Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol 2012; 24:702-710
44. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10:807-814
45. Lee AY, Carrier M. Treatment of cancer-Associated thrombosis: Perspectives on the use of novel oral anticoagulants. Thromb Res 2014; 133:S167-S171
46. Saccullo G, Marietta M, Carpenedo M, et al. Platelet cut-off for anticoagulant therapy in cancer patients with venous thromboembolism and thrombocytopenia: An expert opinion based on RAND/UCLA appropriateness method (RAM). Blood 2013; 122:581
47. Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2011; 3:e2011068
48. Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007; 165-171
49. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011; 29:495-503
50. De La Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-3402.